Endo International PLC (NASDAQ:ENDP)’s share price was down 0.9% on Friday . The stock traded as low as $19.21 and last traded at $20.05, with a volume of 6,611,683 shares changing hands. The stock had previously closed at $20.23.

Several equities analysts recently weighed in on ENDP shares. Morgan Stanley reiterated a “hold” rating and set a $15.00 target price (down from $50.00) on shares of Endo International PLC in a research report on Thursday, May 12th. Vetr upgraded Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 target price on the stock in a research report on Thursday, August 25th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $26.00 target price on shares of Endo International PLC in a research report on Wednesday, May 18th. Leerink Swann downgraded Endo International PLC from an “outperform” rating to a “market perform” rating and set a $23.00 target price on the stock. in a research report on Friday, May 6th. Finally, Barclays PLC lowered their target price on Endo International PLC from $37.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $39.95.

The company has a 50-day moving average price of $20.03 and a 200 day moving average price of $24.76. The firm’s market capitalization is $4.42 billion.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.12. The business earned $921 million during the quarter, compared to analyst estimates of $873.50 million. During the same quarter in the previous year, the company posted $1.08 EPS. The firm’s revenue was up 25.3% on a year-over-year basis. On average, analysts forecast that Endo International PLC will post $4.56 EPS for the current fiscal year.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.